Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5208
Source ID: NCT01422590
Associated Drug: Sitagliptin
Title: Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Sitagliptin|DRUG: Mitiglinide|DRUG: Sitagliptin, Mitiglinide
Outcome Measures: Primary: AUC (area under the curve) of plasma glucose, Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period|AUC of insulin, Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period|AUC of intact GLP-1, Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period|AUC of C-peptide, Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period|AUC of glucagon, Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period|MAGE, Differences of MAGE before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period|AUC of DPP-4 activity, Differences of AUC before treatment (day 1) and after treatment (day 2) is compared between treatment groups, day 1 and day 2 of each period |
Sponsor/Collaborators: Sponsor: Samsung Medical Center | Collaborators: JW Pharmaceutical
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 26
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2010-05
Completion Date: 2011-04
Results First Posted:
Last Update Posted: 2011-09-07
Locations: Samsung Medical Center, Seoul, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT01422590